Locations:
SearchAdvertisement
Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose
Phase 2b trial of aldosterone synthase inhibitor also finds no benefit from dose escalation
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Metabolites from animal product substrates implicated in heart failure development in community cohorts
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Resourceful approaches to the care of patients with microvascular disease and elevated Lp(a)
Study authors urge reevaluation of the sweetener’s safety designation by food regulators
Studies reveal increased cardiac events, enhanced platelet reactivity and thrombotic potential
Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date
Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
Newly identified pathway may explain the so-called niacin paradox
Advertisement
Advertisement